Literature DB >> 9698045

Analgesic effects of 1',1' dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice.

S H Burstein1, E Friderichs, B Kögel, J Schneider, N Selve.   

Abstract

The metabolic pathway leading to carboxylic acid derivatives of cannabinoids was discovered more than twenty years ago. While these compounds showed no cannabimimetic activity, subsequent work documented several biological responses both in vitro and in vivo for the THC acids. These include inhibition of eicosanoid synthesis, antiedema effects, antagonism to PAF actions, inhibition of leucocyte adhesion and anti nociception. In this report we present data further characterizing the analgesic properties of the title substance which is a potent synthetic member of this group. CT3 was effective in the mouse hot plate assay at 48 degrees C showing an ED-50 of 4.31 (3.37-5.83) mg/kg when administered i.v (10% Cremophor EL in saline). When given by gavage in peanut oil, it resulted in 30-40% MPE (maximum possible effect) at 10 mg/kg with the effect persisting for up to 5 hours. A more potent response was observed in the mouse p-phenylquinone writhing test. When given i.v., it showed an ED-50 of 1.24 (0.84-1.75) mg/kg. However, no activity was found with oral administration either in peanut oil or Cremophor EL. At 10 mg/kg i.v., a 100% inhibition of the writhing response was seen. The mouse formalin antinociception test was also studied in animals that received CT3 (4.64 mg/kg) i.v. using three behavioral parameters for activity. The drug showed decreases in each category when compared with vehicle/formalin treated mice. The formalin effect showed a typical two phase, time related, response in which CT3 caused a 64% reduction in the early phase and a 48% reduction in the late phase in a composite score of nociception. Interestingly, it did not alter motor function in the rota rod procedure at 4.64 mg/kg i.v.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698045     DOI: 10.1016/s0024-3205(98)00256-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.

Authors:  Summer Burstein
Journal:  AAPS J       Date:  2005-06-29       Impact factor: 4.009

2.  Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.

Authors:  Silvia Conti; Barbara Costa; Mariapia Colleoni; Daniela Parolaro; Gabriella Giagnoni
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 3.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 4.  Role of cannabinoids in the treatment of pain and (painful) spasticity.

Authors:  Matthias Karst; Sonja Wippermann; Jörg Ahrens
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

Review 5.  The cannabinoid acids, analogs and endogenous counterparts.

Authors:  Sumner H Burstein
Journal:  Bioorg Med Chem       Date:  2014-04-01       Impact factor: 3.641

6.  Liquid chromatography/tandem mass spectrometry method for quantitation of cremophor el and its applications.

Authors:  V Vijaya Bhaskar; Anil Middha
Journal:  Int J Anal Chem       Date:  2013-07-28       Impact factor: 1.885

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.